Patents by Inventor Christos KARAMITROS

Christos KARAMITROS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Engineered primate cystine/cysteine degrading enzymes for therapeutic uses
    Patent number: 12163168
    Abstract: Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, disclosed are modified cystathionine-?-lyases comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, compositions and methods are provided for the treatment of cystinuria using the disclosed modified enzymes or nucleic acids encoding said enzymes.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: December 10, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Everett Stone, Wei-Cheng Lu, Christos Karamitros
  • Human Kynureninase enzymes and uses thereof
    Patent number: 12144828
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: April 6, 2023
    Date of Patent: November 19, 2024
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone, John Blazeck, Christos Karamitros
  • HUMAN KYNURENINASE ENZYMES AND USES THEREOF
    Publication number: 20230405049
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Application
    Filed: April 6, 2023
    Publication date: December 21, 2023
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George GEORGIOU, Everett STONE, John BLAZECK, Christos KARAMITROS
  • Human kynureninase enzymes and uses thereof
    Patent number: 11648272
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: May 16, 2023
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: George Georgiou, Everett Stone, John Blazeck, Christos Karamitros
  • ENGINEERED PRIMATE CYSTINE/CYSTEINE DEGRADING ENZYMES FOR THERAPEUTIC USES
    Publication number: 20210380962
    Abstract: Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, disclosed are modified cystathionine-?-lyases comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, compositions and methods are provided for the treatment of cystinuria using the disclosed modified enzymes or nucleic acids encoding said enzymes.
    Type: Application
    Filed: October 25, 2019
    Publication date: December 9, 2021
    Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Everett STONE, Wei-Cheng LU, Christos KARAMITROS
  • HUMAN KYNURENINASE ENZYMES AND USES THEREOF
    Publication number: 20190350975
    Abstract: Methods and compositions related to the use of a protein with kynureninase activity are described. For example, in certain aspects there may be disclosed a modified kynureninase capable of degrading kynurenine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with kynurenine depletion using the disclosed proteins or nucleic acids.
    Type: Application
    Filed: April 16, 2019
    Publication date: November 21, 2019
    Inventors: George GEORGIOU, Everett STONE, John BLAZECK, Christos KARAMITROS